Loading…
Loading…
PMEDF does not currently pay a dividend.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for PMEDF and 80,000+ other tickers.
See exactly how PMEDF's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for PMEDF and 80,000+ other tickers.
QScreen AI, Inc. is a life sciences technology firm that specializes in pioneering artificial intelligence (AI) solutions. These innovative technologies are designed to enhance general workplace health and safety, and to serve the wider healthcare industry. The company also furnishes specialized tools for medical practitioners. Established on September 3, 1987, its principal operations are based in Toronto, Canada.
Toronto, Ontario--(Newsfile Corp. - July 20, 2026) - QScreen AI Inc. (CSE: QAI) (OTC: PMEDF) (FSE: 3QP) ("QScreen" or the "Company") today announced completion of the tiered screening architecture at the core of its commercialization strategy. The architecture is fully implemented in the Company's browser-based platform and is now being demonstrated to prospective institutional partners through the Company's US channel process, where a first signed evaluation agreement remains the stated near-term milestone.
Toronto, Ontario--(Newsfile Corp. - July 14, 2026) - QScreen AI Inc. (CSE: QAI) (OTC Pink: PMEDF) (FSE: 3QP) ("QScreen" or the "Company") now holds two granted US patents covering its core impairment-detection method, after the United States Patent and Trademark Office granted the Company US Patent No. 12,640,164, "Systems and Methods for Detecting Impairment of an Individual," on May 26, 2026.
Toronto, Ontario--(Newsfile Corp. - June 26, 2026) - QScreen AI Inc. (CSE: QAI) (OTC Pink: PMEDF) (FSE: 3QP) ("QScreen" or "QAI"), an innovator in physiological AI screening, intelligence platform for clinical and occupational health applications, announces that it has elected to voluntarily adopt semi-annual financial reporting and rely on the exemptions in Coordinated Blanket Order 51-933 - Exemptions to Permit Semi-Annual Reporting for Certain Venture Issuers ("CBO 51-933"). Introduced by the Canadian Securities Administrators (CSA), the pilot program under CBO 51-933 allows eligible venture issuers to voluntarily transition from quarterly to semi-annual financial reporting.
Toronto, Ontario--(Newsfile Corp. - June 25, 2026) - QScreen AI Inc. (CSE: QAI) (OTC Pink: PMEDF) (FSE: 3QP) ("QScreen" or "QAI"), an innovator in physiological AI screening, intelligence platform for clinical and occupational health applications, is pleased to announce the closing of the first tranche of its previously announced non-brokered private placement. The Company is pleased to announce that it has completed the first tranche of its previously announced non-brokered private placement through the issuance of 4,876,400 units (the "Units") at a price of $0.05 per Unit for gross proceeds of approximately $243,820.
Toronto, Ontario--(Newsfile Corp. - June 1, 2026) - QScreen AI Inc. (CSE: QAI) (OTC Pink: PMEDF) (FSE: 3QP) ("QScreen" or "QAI"), an innovator in physiological AI screening, today announced that members of its senior leadership team will participate in a five-city investor roadshow across Central Europe from June 1 to June 5, 2026. Date City June 1 Munich, Germany June 2 Ljubljana, Slovenia June 3 Budapest, Hungary June 4 Bratislava, Slovakia June 5 Vienna, Austria Advancing Platform Development and Strategic Reach Over recent months, QScreen has continued to expand both its technology platform and strategic advisory network.